Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.81−0.04 (-0.14%)
Close on Nov 18, 2026Market cap $4.83BP/E –Yield –
Cogent Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cogent Biosciences's revenue for the twelve months ending Dec 31, 2020 was $7.87M, down 65.0% year over year. For fiscal 2020 it was $7.87M, down 65.0% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $7.87M | -65.0% |
| FY2019 | Dec 31, 2019 | $22.50M | +131.1% |
| FY2018 | Dec 31, 2018 | $9.73M | +16.4% |
| FY2017 | Dec 31, 2017 | $8.36M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $312.00K | -69.4% |
| Q2 FY2020 | Jun 30, 2020 | $528.00K | -83.2% |
| Q1 FY2020 | Mar 31, 2020 | $7.03M | +130.3% |
| Q4 FY2019 | Dec 31, 2019 | $15.29M | +301.8% |
| Q3 FY2019 | Sep 30, 2019 | $1.02M | -50.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.14M | +88.4% |
| Q1 FY2019 | Mar 31, 2019 | $3.05M | +37.5% |
| Q4 FY2018 | Dec 31, 2018 | $3.81M | +79.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.04M | -12.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.67M | -19.9% |
| Q1 FY2018 | Mar 31, 2018 | $2.22M | +21.5% |
| Q4 FY2017 | Dec 31, 2017 | $2.12M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.33M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.83M | – |
See a number that looks wrong?